These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7986180)

  • 21. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations.
    Inzelberg R; Nisipeanu P; Rabey JM; Orlov E; Catz T; Kippervasser S; Schechtman E; Korczyn AD
    Neurology; 1996 Sep; 47(3):785-8. PubMed ID: 8797480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys.
    Bélanger N; Grégoire L; Hadj Tahar A; Bédard PJ
    Mov Disord; 2003 Dec; 18(12):1436-41. PubMed ID: 14673879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations.
    Steiger MJ; El-Debas T; Anderson T; Findley LJ; Marsden CD
    J Neurol; 1996 Jan; 243(1):68-72. PubMed ID: 8869390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.
    Fariello RG
    Drugs; 1998; 55 Suppl 1():10-6. PubMed ID: 9483165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease.
    Del Dotto P; Colzi A; Musatti E; Strolin Benedetti M; Persiani S; Fariello R; Bonuccelli U
    Clin Neuropharmacol; 1997 Oct; 20(5):455-65. PubMed ID: 9331523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopamine agonist monotherapy in Parkinson's disease.
    Clarke CE; Guttman M
    Lancet; 2002 Nov; 360(9347):1767-9. PubMed ID: 12480442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term effects of cabergoline and levodopa in Japanese patients with early Parkinson's disease: a 5-year prospective study.
    Utsumi H;
    Acta Med Okayama; 2012; 66(2):163-70. PubMed ID: 22525474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cabergoline in Parkinson's disease: long-term follow-up.
    Lera G; Vaamonde J; Rodriguez M; Obeso JA
    Neurology; 1993 Dec; 43(12):2587-90. PubMed ID: 7902970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual dopamine agonist treatment in Parkinson's disease.
    Stocchi F; Vacca L; Berardelli A; Onofrj M; Manfredi M; Ruggieri S
    J Neurol; 2003 Jul; 250(7):822-6. PubMed ID: 12883924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cabergoline : a review of its use in the treatment of Parkinson's disease.
    Curran MP; Perry CM
    Drugs; 2004; 64(18):2125-41. PubMed ID: 15341508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of two different dopamine agonists in the management of Parkinson's disease.
    Stocchi F; Berardelli A; Vacca L; Thomas A; De Pandis MF; Modugno N; Valente M; Ruggieri S
    Neurol Sci; 2002 Sep; 23 Suppl 2():S115-6. PubMed ID: 12548370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson's disease.
    Baas HK; Schueler P
    Eur Neurol; 2001; 46 Suppl 1():18-23. PubMed ID: 11741099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study.
    Fénelon G; Giménez-Roldán S; Montastruc JL; Bermejo F; Durif F; Bourdeix I; Péré JJ; Galiano L; Schadrack J
    J Neural Transm (Vienna); 2003 Mar; 110(3):239-51. PubMed ID: 12658373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
    Utsumi H; Okuma Y; Kano O; Suzuki Y; Iijima M; Tomimitsu H; Hashida H; Kubo S; Suzuki M; Nanri K; Matsumura M; Murakami H; Hattori N;
    Intern Med; 2013; 52(3):325-32. PubMed ID: 23370739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lifecorder: a new device for the long-term monitoring of motor activities for Parkinson's disease.
    Saito N; Yamamoto T; Sugiura Y; Shimizu S; Shimizu M
    Intern Med; 2004 Aug; 43(8):685-92. PubMed ID: 15468966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cabergoline in the treatment of Parkinson's disease].
    Pastor P; Tolosa E
    Neurologia; 2003 May; 18(4):202-9. PubMed ID: 12721865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long term tolerability of high dose ergoline derived dopamine agonist therapy for the treatment of Parkinson's disease.
    Navan P; Bain PG
    J Neurol Neurosurg Psychiatry; 2002 Nov; 73(5):602-3. PubMed ID: 12397168
    [No Abstract]   [Full Text] [Related]  

  • 38. Ropinirole for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2000; (3):CD001516. PubMed ID: 10908503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease.
    Högl B; Rothdach A; Wetter TC; Trenkwalder C
    Neuropsychopharmacology; 2003 Oct; 28(10):1866-70. PubMed ID: 12865895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
    Cattaneo C; Sardina M; Bonizzoni E
    J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.